Skip to main content

Ex-Sarepta CEO takes helm of genetic disease startup Stoke

In an interview, Ed Kaye said that he had “many opportunities” after leaving the Cambridge biotech last year, but chose Stoke partly because of his connection to one of its cofounders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.